|
|
 All omega of the active B12 group 3 reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal essential congestion fatty and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 acid on were presented by Dr. O''Connor omega to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the 3 statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied essential five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The fatty test was repeated acid after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm omega did not develop in the second 3 metabisulfite challenge.6 Studies indicate essential that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream fatty before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World acid Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, omega urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two 3 and essential sites in Riverside County, CA in 1989. Sixteen of fatty the 17 subjects had lowered IgE levels from Day 0 to Day 30.3 In acid January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy omega and 3 (hay fever) symptoms this spring to essential the last two springs? 20 people responded, with fatty 15 reporting having acid had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence omega study 3 showed that a 3000 mcg lozenge delivered essential an equivalent amount of cyanocobalamin fatty and acid to the blood as a 15 mcg injection.9 From the spring to the summer omega and 3 patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive essential days. All subjects also received C and B oral multivitamins fatty for 21 days. Twice daily subjects maintained a nine-week acid diary on sneezing, omega runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded 3 on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total essential weekly symptom/rescue medication for the active group compared fatty to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those acid of the studies on injectable cyanocobalamin.10 If you are looking to loose weight but don't have time to do all those activities you must do to even loose a pound? Well do we have the fat burning supplements your looking for. Come in and check us out! Our site is very easily navigated.
|